XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Interest in joint venture (Tables)
9 Months Ended
Sep. 30, 2023
Interests In Other Entities [Abstract]  
Schedule of movement in interest in joint venture The table below provides a rollforward of the Company’s interest in Overland ADCT BioPharma as of September 30, 2023 and 2022, respectively.
(in KUSD)
Interest in joint venture
January 1, 202331,152 
Share of comprehensive loss in joint venture(4,163)
September 30, 202326,989 
January 1, 202241,236 
Share of comprehensive loss in joint venture(6,549)
September 30, 202234,687 
Summary of financial information in join venture
The tables below provide summarized financial information for Overland ADCT BioPharma that is material to the Company. The following information reflects the amounts presented in the financial statements of Overland ADCT BioPharma and not the Company’s share of those amounts.
(in KUSD)As of
Summarized Balance SheetSeptember 30, 2023December 31, 2022
Cash and cash equivalents9,238 19,261 
Prepaid and other current assets364 
Intangible assets49,249 49,249 
Total liabilities(3,553)(3,062)
Net assets55,298 65,450 
Summarized Statement of Comprehensive LossThree months ended September 30,Nine months ended September 30,
2023202220232022
Loss from operations2,750 4,950 8,278 14,317 
Other expense (income)126 (604)(1,057)(1,308)
Other comprehensive loss (income)(157)— 1,274 — 
Total comprehensive loss2,719 4,346 8,495 13,009